Health Canada Approves Mirum Pharma's Livmarli Tablet Formulation; Stock Up

Group 1 - Mirum Pharmaceuticals received approval from Health Canada for the tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) [1] - Following the approval announcement, Mirum's shares increased by over 5% in pre-market trading [1] - ALGS is a rare genetic disorder that can cause cholestasis and severe itching due to bile duct abnormalities [1] Group 2 - Livmarli was previously approved in Canada as an oral solution for ALGS patients aged 12 months and older [2] - Health Canada also authorized Livmarli for treating cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC) [2] - Mirum Pharmaceuticals shares closed at $103.96 on Wednesday, reflecting a decrease of 1.41% [2]